| References: |
LY2409881 is a novel inhibitor of IκB kinase β (IKK2). LY2409881 inhibited constitutively activated NF-κB, and caused concentration- and time-dependent growth inhibition and apoptosis in lymphoma cells. In models of diffuse large B-cell lymphoma (DLBCL), the cytotoxicity of LY2409881 correlated with the overall activation status of NF-κB, but not simply in a pattern predicted by the cell-of-origin classification of these cell lines. LY2409881 was safe to mice at three dose levels, 50, 100, and 200 mg/kg, all of which caused significant inhibition of tumor growth. LY2409881 suppressed the activity of the NF-κB subunit p65 in lymphoma cells treated by the HDAC inhibitor romidepsin, underlying a potential mechanism of the marked synergy observed of these two drugs. For the detailed information of LY2409881 trihydrochloride, the solubility of LY2409881 trihydrochloride in water, the solubility of LY2409881 trihydrochloride in DMSO, the solubility of LY2409881 trihydrochloride in PBS buffer, the animal experiment (test) of LY2409881 trihydrochloride, the cell expriment (test) of LY2409881 trihydrochloride, the in vivo, in vitro and clinical trial test of LY2409881 trihydrochloride, the EC50, IC50,and affinity,of LY2409881 trihydrochloride, For the detailed information of LY2409881 trihydrochloride, the solubility of LY2409881 trihydrochloride in water, the solubility of LY2409881 trihydrochloride in DMSO, the solubility of LY2409881 trihydrochloride in PBS buffer, the animal experiment (test) of LY2409881 trihydrochloride, the cell expriment (test) of LY2409881 trihydrochloride, the in vivo, in vitro and clinical trial test of LY2409881 trihydrochloride, the EC50, IC50,and affinity,of LY2409881 trihydrochloride, Please contact DC Chemicals. |
